Cargando…
Dual inhibition of SARS-CoV-2 and human rhinovirus with protease inhibitors in clinical development
The 3-chymotrypsin-like cysteine protease (3CLpro) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is considered a major target for the discovery of direct antiviral agents. We previously reported the evaluation of SARS-CoV-2 3CLpro inhibitors in a novel self-assembled monolayer deso...
Autores principales: | Liu, Cheng, Boland, Sandro, Scholle, Michael D., Bardiot, Dorothee, Marchand, Arnaud, Chaltin, Patrick, Blatt, Lawrence M., Beigelman, Leonid, Symons, Julian A., Raboisson, Pierre, Gurard-Levin, Zachary A., Vandyck, Koen, Deval, Jerome |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Author(s). Published by Elsevier B.V.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7839511/ https://www.ncbi.nlm.nih.gov/pubmed/33515606 http://dx.doi.org/10.1016/j.antiviral.2021.105020 |
Ejemplares similares
-
Evaluation of SARS-CoV-2 3C-like protease inhibitors using self-assembled monolayer desorption ionization mass spectrometry
por: Gurard-Levin, Zachary A., et al.
Publicado: (2020) -
ALG-097111, a potent and selective SARS-CoV-2 3-chymotrypsin-like cysteine protease inhibitor exhibits in vivo efficacy in a Syrian Hamster model
por: Vandyck, Koen, et al.
Publicado: (2021) -
The Substitutions L50F, E166A, and L167F in SARS-CoV-2 3CLpro Are Selected by a Protease Inhibitor In Vitro and Confer Resistance To Nirmatrelvir
por: Jochmans, Dirk, et al.
Publicado: (2023) -
Considerations for the discovery and development of 3-chymotrypsin-like cysteine protease inhibitors targeting SARS-CoV-2 infection
por: Vandyck, Koen, et al.
Publicado: (2021) -
Label-Free Screening of SARS-CoV-2 NSP14 Exonuclease Activity Using SAMDI Mass Spectrometry
por: Scholle, Michael D., et al.
Publicado: (2021)